Alpha-synuclein dysfunction in Lewy body diseases

Movement Disorders

Volumn 20, Issue SUPPL. 12, 2005, Pages

  Tofaris, George K ^a   Spillantini, Maria Grazia ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Lewy body diseases; Neurodegeration; Parkinson's disease; Protein folding; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER;

ALPHA HELIX; BETA SHEET; BRAIN NERVE CELL; CYTOLOGY; CYTOTOXICITY; DIFFUSE LEWY BODY DISEASE; GENE MUTATION; HUMAN; LIPID MEMBRANE; METABOLIC DISORDER; MOLECULAR MECHANICS; NERVE DEGENERATION; NEURITE; NEUROFILAMENT; NEUROPROTECTION; NONHUMAN; PLASTICITY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

ALPHA-SYNUCLEIN; ANIMALS; CHROMOSOMES, HUMAN, PAIR 6; CYTOSKELETON; DROSOPHILA; HUMANS; LEWY BODY DISEASE; MICE; PARKINSON DISEASE; PHENOTYPE; PHOSPHORYLATION; POINT MUTATION;

EID: 26444544353     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20538     Document Type: Review

References (75)

1. Maroteaux L, Campanelli JT, Scheller RH. Synuclein: a neuron specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 1988;8:2804-2815.
2. Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, Otero DA, Kondo J, Ihara Y, Saitoh T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1993;90:11282-11286.
3. Jakes R, Spillantini MG, Goedert M. Identification of two distinct synucleins from the human brain. FEBS Lett 1994;345:27-32.
4. Tobe T, Nakajo S, Tanaka A, Mitoya A, Omata K, Nakaya K, Tomita M, Nakamura Y. Cloning and characterization of the cDNA encoding a novel specific 14 kDa protein. J Neurochem 1992;59:1624-1629.
5. Ji H, Liu YE, Jia T, Wang M, Liu J, Xiao G, Joseph BK, Rosen C, Shi YE. Identification of a breast cancer specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res 1997;57:759-764.
6. Spillantini MG, Divane A, Goedert M. Assignment of human α-synuclein (SNCA) and β-synuclein (SNCB) genes to chromosomes 4q21 and 5q35. Genomics 1995;27:379-381.
7. Ueda K, Saitoh T, Mori H. Tissue-dependent alternative splicing of mRNA for NACP, the precursor of non-Aβ component of Alzheimer's disease amyloid. Biochem. Biophys Res Commun 1994;205: 1366-1372.
8. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001;2:492-501.
9. Irizarry MC, Kim TW, McNamara M, Tanzi RE, George JM, Clayton DF, Hyman BT. Characterization of the precursor ptotein of the non-A-beta component of senile plaques (NACP) in the human central nervous system. J Neuropath Exp Neurol 1996;55: 889-895.
10. George JM, Jin H, Woods WS, Clayton DF. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 1995;15:361-372.
11. Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, Rohan de Silva H, Kittel A, Saitoh T. The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995;14:467-475.
12. Buchman VL, Hunter HJ, Pinon LG, Thompson J, Privalova EM, Ninkina NN, Davies AM. Persyn, a member of the synuclein family, has distinct pattern of expression in the developing nervous system. J Neurosci 1998;18:9335-9341.
13. Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT. NACP, a protein implicated in Alzheimer's disease and learning is natively unfolded. Biochemistry 1996;35:13709-13715.
14. Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 1998;273:9443-9449.
15. Jenco JM, Rawlingson A, Daniels B, Morris AJ. (1998) Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by α- and β-synucleins. Biochemistry 1998; 37:4901-4909.
16. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A. Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000; 25:239-252.
17. Murphy DD, Rueter SM, Trojanowski JQ, Lee VM. Synucleins are developmentally expressed and α-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 2000;20:3214-3220.
18. Dev KK, Hofele K, Barbieri S, Buchman VL, van der Putten H. Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology 2003;45:14-44.
19. Engelender S, Kaminsky Z, Guo X, Sharp AH, Amaravi RK, Kleiderlein JJ, Margolis RL, Troncoso JC, Lanahan AA, Worley PF, Dawson VL, Dawson TM, Ross CA. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat Genet 1999;22:110-114.
20. Ostrerova-Golts N, Petrucelli L, Farer M, Mehta N, Alexander P, Choi P, Palacino J, Hardy J, Lee JM, Wolozin B. α-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci 1999;19:5782-5791.
21. Iwata A, Maruyama M, Kanazawa I, Nukina N. α-Synuclein affects the MAP kinase pathway and accelerates cell death. J Biol Chem 2001;276:45320-45329.
22. Alves da Costa C, Ancolio K, Checler F. Wild-type but not Parkinson's disease-related Ala-53-Thr mutant α-synuclein protects neuronal cells from apoptotic stimuli. J Biol Chem 2000;275: 24065-24069.
23. Lee M, Hyun D, Halliwell B, Jenner P. Effect of the over-expression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J Neurochem 2001;76:998-1009.
24. Hashimoto M, Hsu LJ, Rockenstein E, Takenouchi T, Mallory M, Masliah E. α-Synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress signaling pathway in neuronal cells. J Biol Chem 2002;277:11465-11472.
25. Okochi M, Walter J, Koyama A, Nakajo S, Baba M, Iwatsubo T, Meijer L, Kahle PJ, Haass C. Constitutive phosphorylation of the Parkinson's disease associated α-synuclein. J Biol Chem 2000; 275:390-397.
26. Pronin AN, Morris AJ, Surguchov A, Benovic JL. Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J Biol Chem 2000;275:26515-26522.
27. Negro A, Brunati AM, Donella-Deana A, Massimino ML, Pinna LA. Multiple phosphorylation of α-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation. FASEB J 2002; 16:210-212.
28. Culvenor JG, McLean CA, Cutt S, Campbell BC, Maher F, Jakala P, Hartmann T, Beyreuther K, Masters CL, Li QX. Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid. Am J Pathol 1999;155:1173-1181.
29. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996;55:259-272.
30. Polymeropoulos MH, Lavendan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos E.S, Chandrasekharappa S, Athanasiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Dilorio G, Golbe LI, Nussbaum RL. Mutation in α-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
31. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schos L, Riess O. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet 1998; 18:106-108.
32. Chartier-Harlin MC, Kachergus J, Roumier C, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004;364:1167-1169.
33. Ibanez P, Bonnet AM, Débarges B, et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004;364:1169-1171.
34. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003;302:841.
35. Zarranz J.J, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes JG. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004;55:164-173.
36. Kruger R, Vieira-Saecker AM, Kuhn W, Berg D, Muller T, Kuhnl N, Fuchs GA, Storch A, Hungs M, Woitalla D, Przuntek H, Epplen JT, Schols L, Riess O. Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype. Ann Neurol 1999;45:611-617.
37. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy Bodies. Nature 1997;338: 839-840.
38. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 1998;95:6469-6473.
39. Crowther RA, Jakes R, Spillantini MG, Goedert M. Synthetic filaments assembled from C-terminally truncated α-synuclein. FEBS Lett 1998;436:309-312.
40. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson's disease. Nat Med 1998;4:1318-1320.
41. Arima K, Ueda K, Sunohara N, Hirai S, Izumiyama Y, Tonozuka-Uehara H, Kawai M. Immunoelectron microscopic demonstration of NACP/α-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies. Brain Res 1998;808:93-100.
42. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 1998;251:205-208.
43. Tu PH, Galvin JE, Baba M, Giasson B, Tomita T, Leight S, Nakajo S, Iwatsubo T, Trojanowski JQ, Lee VM. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α-synuclein. Ann Neurol 1998;44:415-422.
44. Arai K, Kato N, Kashiwado K, Hattori T. Pure autonomic failure in association with human α-synucleinopathy. Neurosci Lett 2000; 296:171-173.
45. Arawaka S, Saito Y, Murayama S, Mori H. Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for α-synuclein. Neurology 1998;51:887-889.
46. Wakabayashi K, Yoshimoto M, Fukushima T, Koide R, Horikawa Y, Takahashi H. Widespread occurrence of α-synuclein /NACP-immunoreactive neuronal inclusions in juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies. Neuropathol Appl Neurobiol 1999;25:363-368.
47. Yamazaki M, Arai Y, Baba M, Iwatsubo T, Mori O, Katayama Y, Oyanagi K. α-Synuclein inclusions in amygdala in the brains of patients with the parkinsonism-dementia complex of Guam. J Neuropathol Exp Neurol 2000;59:585-591.
48. Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ. Antibodies to α-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann Neurol 1999;45:353-357.
49. Kotzbauer PT, Trojanowski JQ, Lee VM. Lewy body pathology in Alzheimer's disease. J Mol Neurosci 2001;17:225-232.
50. Narhi L, Wood SJ, Steavenson S, Jiang Y, Wu GM, Anafi D, Kaufman SA, Martin F, Sitney K, Denis P, Louis JC, Wypych J, Biere AL, Citron M. Both familial Parkinson's disease mutations accelerate α-synuclein aggregation. J Biol Chem 1999;274:9843-9846.
51. Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA. Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross beta conformation. Proc Natl Acad Sci USA 2000; 97:4897-4902.
52. Conway KA, Lee SL, Rochet JC, Ding TT, Williamson RE, Lansbury PT. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 2000;97:571-576.
53. Jensen PH, Nielsen MH, Jakes R, Dotti CG, Goedert M. Binding of α-synuclein to rat brain vesicles is abolished by familial Parkinson's disease mutation. J Biol Chem 1998;273:26292-26294.
54. Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, Biere AJ. α-Synuclein fibrillogenesis is nucleation-dependent. J Biol Chem 1999;274:19509-19512.
55. Uversky V, Li J, Fink AL. Evidence for a partially folded intermediate in α-synuclein fibril formation. J Biol Chem 2001;276: 10737-10744.
56. Uversky V, Li J, Souillac P, Jakes R, Goedert M, Fink AL. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of α-synuclein assembly by β- and γ-synuclein. J Biol Chem 2002;277:11970-11978.
57. Giasson BI, Murray IV, Trojanowski JQ, Lee VM. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem 2001;276:2380-2386.
58. Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M, Wong J, Takenouchi T, Hashimoto M, Masliah E. α-Synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 2000;157:401-410.
59. Tabrizi SJ, Orth M, Wilkinson JM, Taanman JW, Warner TT, Cooper JM, Schapira AH. Expression of mutant α-synuclein causes increased susceptibility to dopamine toxicity. Hum Mol Genet 2000;9:2683-2689.
60. Tofaris GK, Layfield R, Spillantini MG. α-Synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett 2001;509:22-26.
61. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Muche L. Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 2000;287:1265-1269.
62. van der Putten H, Wiederhold KH, Probst A, Barbieri S, Mistl C, Danner S, Kauffmann S, Hofele K, Spooren WP, Ruegg MA, Lin S, Caroni P, Sommer B, Tolnay M, Bilbe G. Neuropathology in mice expressing human α-synuclein. J Neurosci 2000;20:6021-6029.
63. Kahle PJ, Neumann M, Ozmen L, Muller V, Odoy S, Okamoto N, Jacobsen H, Iwatsubo T, Trojanowski JQ, Takahashi H, Wakabayashi K, Bogdanovic N, Riederer P, Kretzschmar HA, Haass C. Selective insolubility of α-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol 2001; 159:2215-2225.
64. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron 2002;34: 521-533.
65. Lee M.K, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, Dawson TM, Copeland NG, Jenkins NA, Price DL. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala53Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci USA 2002;99: 8968-8973.
66. Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, Spooren W, Muller V, Odoy S, Fujiwara H, Hasegawa M, Iwatsubo T, Trojanowski JQ, Kretzschmar HA, Haass C. Misfolded proteinase K-resistant hyperphosphorylated α-synuclein in aged transgenic mice with locomotor deterioration and in human α-synucleinopathies. J Clin Invest 2002;110:1429-1439.
67. Matsuoka Y, Vila M, Lincoln S, McCormack A, Dickson D, Langston WJ, McGowan E, Farrer M, Hardy J, Duff K, Przedborski S, Di Monte DA. Lack of nigral pathology in transgenic, mice expressing human α-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol Dis 2001;8:535-539.
68. Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature 2000;404:394-398.
69. Ostrerova-Golts N, Petrucelli L, Hardy J, Lee JM, Farer M, Wolozin B. The A53T α-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 2000;20:6048-6054.
70. Betarbet R, Sherer TB, McKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2001;3:1301-1306.
71. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurting HI, Ischiropoulos H, Trojanowski JQ, Lee VM. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science 2000;290:985-989.
72. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T. α-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002;4:160-164.
73. Tofaris G.K., Razzaq A, Ghetti B, Lilley KS, Spillantini MG. Ubiquitination of α-Synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem 2003;278:44405-44411.
74. Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E. β-Synuclein inhibits α-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 2001;32:213-223.
75. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Chaperone suppression of α-synuclein toxicity in a Drosiphila model for Parkinson's disease. Science 2002;295:865-868.